

Stanford study ID	Name	Description	Vaccines	Data in FluPRINT
SLVP015	Comparison of immune responses to influenza vaccine in adults of different ages (2007-2017)	Who: 18-100yo healthy participants How: immunized annually with the seasonal inactivated influenza vaccines from 2007-2017 When: Blood samples acquired before immunization (Day 0), on days 6-8 and 28 after immunization	2007-2013 Seasonal trivalent, inactivated influenza vaccines (Fluzone) 2014-2015 High Dose trivalent Fluzone for participants <i>geq</i> 65yo and quadrivalent Fluzone for younger participants	135 donors Assays: 51-plex Luminex 62-plex Luminex MSD 4plex MSD9plex Other Luminex HAI CMV/EBV Hormones CyTOF phenotype Lyoplate Phospho Cytof pheno Phospho cytof phospho Phosphoflow CBCD
SLVP017	B-cell immunity to influenza (2009-2011 and 2013)	Who: 1-2yo (2013), 8-100yo healthy participants who did not receive the seasonal influenza vaccine in previous years (2010, 2011 and 2013) How: immunized with either seasonal inactivated or live, attenuated influenza vaccines in 2009, 2010, 2011 and 2013 When: Blood samples acquired before immunization (Day 0) and on day 28 after immunization	2009-2011 Seasonal trivalent, inactivated influenza vaccines (Fluzone) or seasonal live, attenuated influenza vaccine (FluMist) 2013 Seasonal trivalent inactivated influenza vaccine- (Fluzone) - pediatric formulation for 1-2yo children	153 donors Assays: 51-plex Luminex 62-plex Luminex HAI CMV/EBV CyTOF phenotype CBCD
SLVP018	T-cell and general immune response to seasonal influenza vaccine (2009-2013)	Who: 1-8yo (2013), 8-100yo healthy participants How: immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2009-2013 When: Blood samples acquired before immunization (Day 0), days 7-10 and 28 after immunization	2009-2010 Seasonal trivalent inactivated influenza vaccine (Fluzone) or seasonal trivalent live attenuated influenza vaccine (FluMist) 2010 High Dose trivalent Fluzone for participants <i>geq</i> 65yo 2013 Seasonal trivalent, inactivated influenza Pediatric Dose (Fluzone, 0.25 ml) for 1-3yo children	249 donors Assays: 51-plex Luminex 62-plex Luminex MSD 4plex MSD 9plex HAI CMV/EBV Hormones CyTOF phenotype Lyoplate Phospho Cytof pheno Phospho cytof phospho Phosphoflow CBCD
SLVP021	Plasmablast trafficking and antibody response in influenza vaccination (2011-2014)	Who: 8-34yo healthy participants who did not receive the seasonal influenza vaccine in previous years How: immunized with either seasonal inactivated influenza vaccines, given intramuscularly or intradermally, or live, attenuated influenza vaccines from 2011-2014 When: Blood samples acquired before immunization (Day 0), days 6-8 and 24-32 after immunization	2011-2014 Seasonal trivalent inactivated influenza vaccine (Fluzone) given either intramuscularly or intradermally 2011-2012 Seasonal trivalent live attenuated influenza vaccine (FluMist)	84 donors Assays: 51-plex Luminex 62-plex Luminex HAI CMV/EBV Hormones CyTOF phenotype Phospho Cytof pheno Phospho cytof phospho Phosphoflow CBCD
SLVP024	Protective mechanisms against a pandemic respiratory virus (2012)	Who: 2-9yo healthy participants How: immunized with the seasonal live, attenuated influenza vaccine When: Blood samples only from 18-2yo adults acquired before immunization (Day 0), days 7 and 28 after immunization	Seasonal live, attenuated influenza vaccine (FluMist)	Donors: 8 Assays: HAI Phosphoflow
SLVP028	Genetic and environmental factors in the response to influenza vaccination (2014-2018)	Who: 12-9yo healthy participants How: immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2014-2018 When: Blood samples acquired before immunization (Day 0), days 6-8 and 28 + 7 after immunization	Seasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist)	Donors: 52 Assays: 62-plex Luminex HAI CMV/EBV Hormones CyTOF phenotype
SLVP029	Innate and acquired immunity to influenza infection and immunization (2014-2017)	Who: 6 mo-49yo healthy participants (who did not receive LAIV in the prior season nor received influenza immunizations in two or more prior seasons) How: immunized with either seasonal inactivated or live, attenuated influenza vaccines from 2014-2017 When: Blood samples acquired before immunization (Day 0), days 7 and 28 after immunization. Children \geq 9 yrs received 2 immunizations with the second blood samples acquired 28 days after second immunization	Seasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist)	Donors: 47 Assays: 62-plex Luminex HAI CMV/EBV Hormones CyTOF phenotype
SLVP030	The role of CD4+ memory phenotype, memory, and effector t cells in vaccination and infection (2014-2019)	Who: 6 mo-10yo healthy participants How: immunized annually with either seasonal inactivated or live, attenuated influenza vaccines from 2014-2019 When: Blood samples acquired before immunization (Day 0), days 7 and 60 after immunization. Children with no prior influenza vaccine received 2 immunizations with the second blood sample acquired 60 days after second immunization	Seasonal quadrivalent inactivated influenza vaccine (Fluzone) or seasonal quadrivalent live attenuated influenza vaccine (FluMist) Seasonal trivalent, inactivated influenza Pediatric Dose (Fluzone, 0.25 ml) for 6-35mo children	Donors: 12 Assays: 62-plex Luminex HAI CMV/EBV Hormones CyTOF phenotype